VivoSeq
Other

Nosocomial Infection

12

Pipeline Programs↗

2

Active Trials↗

6

Companies Involved↗

Nosocomial Infection is an emerging landscape with 12 programs across 6 companies. The most active players are Eastern Cooperative Oncology Group, Hikma Pharmaceuticals LLC, Solvay Pharmaceuticals. 4 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

80/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Eastern Cooperative Oncology Group

1 program

Phase 3H

Hikma Pharmaceuticals LLC

1 program

ApprovedS

Solvay Pharmaceuticals

1 program

PreclinicalAstellas logo

Astellas

1 program

PreclinicalSanofi logo

Sanofi

1 program

PreclinicalPfizer logo

Pfizer

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

94%

Small molecule

15 of 16 classified programs — the dominant modality here.

6%ALL OTHERSProtein / enzyme16%

Small molecule leads; the ring shows all 16 classified programs, each share of the total. Modality classified for 100% of 16 pipeline programs.

Analysis

Trial Status

10

clinical trials

Completed4 · 40%
Unknown status3 · 30%
Not yet recruiting1 · 10%
Enrolling by invitation1 · 10%
Terminated1 · 10%

Clinical Trials

Trial Activity

10 trials

Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.
Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06818565·150 enrolled
The Prophylactic Effect of Garlic Tablets to Prevent Nosocomial Infections in Intensive Care Unit Patients.
Enrolling by invitation·—·Phase 3·NCT06833125·62 enrolled
Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit
Completed·—·N/A·NCT01640925·350 enrolled
Prevention of Nosocomial Infection by Decontamination of the Naso- and Oropharynx With Chlorhexidine (NONI Trial)
Completed·—·Phase 2/3·NCT00272675·1,000 enrolled
Study of Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit
Completed·JJohns Hopkins University·Phase 2/3·NCT00549393·5,659 enrolled
Prevention Trial of Nosocomial Infections in Neutropenic Prematures With G-CSF
Completed·UUniversity Hospital, Strasbourg, France·Phase 3·NCT00213759·200 enrolled
ICULIP, Influence of Two Lipid Emulsions in the Nosocomial Infection in Critical Patients
Terminated·BB. Braun Medical Inc.·Phase 4·NCT00396461·212 enrolled
Lactulose for the Prevention of Nosocomial Infections in Children
Unknown status·—·N/A·NCT00273949·100 enrolled
Prolonged Infusion Cefepime and Nosocomial Infections
Unknown status·HHospital de Clinicas de Porto Alegre·Phase 3·NCT02568800·134 enrolled
Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants
Unknown status·AAgennix·Phase 1/2·NCT00854633·120 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)